Brian Scott Higgins

US Patent:

7951405, May 31, 2011

Filed:

Jun 3, 2005

Appl. No.:

11/145495

Inventors:

Brian Higgins - Nutley NJ, US
Kenneth Kolinsky - Nutley NJ, US

Assignee:

OSI Pharmaceuticals, LLC - Farmingdale NY

International Classification:

A61K 33/24
A61K 31/517

US Classification:

424649, 5142662

Abstract:

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and cisplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and cisplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

US Patent:

8426798, Apr 23, 2013

Filed:

Aug 19, 2010

Appl. No.:

12/859735

Inventors:

Brian Higgins - Oxford CT, US
Gregory J. McBrien - Glastonbury CT, US

Assignee:

JDS Uniphase Corporation - Milpitas CA

International Classification:

G01J 1/44

US Classification:

250214C, 2502141, 25022711, 359238, 359245

Abstract:

An electrical termination circuit for a traveling wave optoelectronic device is disclosed. The electrical termination circuit is constructed to reflect a portion of a radio-frequency signal back into the optoelectronic device. The reflected signal is out of phase with the applied radio-frequency signal at a frequency of a detrimental spectral feature or a bump in an electro-optical transfer characteristic of the optoelectronic device. The amplitude and the phase of the reflected signal are selected so as to suppress the detrimental spectral feature without a significant reduction in the efficiency of electro-optical or optical-electrical transformation of the optoelectronic device.

US Patent:

8487772, Jul 16, 2013

Filed:

Dec 12, 2009

Appl. No.:

12/636736

Inventors:

Brian William Higgins - Dayton MD, US

International Classification:

G08B 23/00

US Classification:

3405731, 3405734, 34053926, 34053929, 3401462, 340500, 340501, 3404571, 340 52, 340 56, 600300, 600306, 600307, 600346, 600549

Abstract:

A system and method for effectively communicating information using at least one mode of communication is described, in which information recipients proximate to a communications device within a pre-determined space and during a pre-determined time period are identified, from whom physiological state information is obtained that, when coupled with other characteristics information, is used to select from a plurality of information elements at least one information element to better target the information elements. The information element is then provided to the communications device so that it may be provided to the information recipients in the pre-determined space in a manner that is sensed by the information recipients.

US Patent:

20050272688, Dec 8, 2005

Filed:

Jun 3, 2005

Appl. No.:

11/144952

Inventors:

Brian Higgins - Nutley NJ, US
Kenneth Kolinsky - Nutley NJ, US

International Classification:

A61K031/7072
A61K031/498

US Classification:

514049000, 514249000

Abstract:

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and gemcitabine combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

US Patent:

20050272737, Dec 8, 2005

Filed:

Jun 3, 2005

Appl. No.:

11/144855

Inventors:

Jianping Chen - Nutley NJ, US
Brian Higgins - Nutley NJ, US
Kenneth Kolinsky - Nutley NJ, US

International Classification:

A61K039/395
A61K031/498

US Classification:

514249000, 424143100

Abstract:

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and irinotecan combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and irinotecan combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

US Patent:

20050272738, Dec 8, 2005

Filed:

Jun 3, 2005

Appl. No.:

11/145091

Inventors:

Jianping Chen - Nutley NJ, US
Brian Higgins - Nutley NJ, US
Kenneth Kolinsky - Nutley NJ, US

International Classification:

A61K031/498
A61K031/28

US Classification:

514249000, 514492000

Abstract:

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and oxaliplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and oxaliplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

US Patent:

20130245089, Sep 19, 2013

Filed:

Feb 5, 2013

Appl. No.:

13/759647

Inventors:

Brian Higgins - Fresh Meadows NY, US
Gwen Nichols - New York NY, US
Kathryn Packman - Bloomfield NJ, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

A61K 31/40

US Classification:

514423

Abstract:

There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.

US Patent:

20130346550, Dec 26, 2013

Filed:

Jul 15, 2013

Appl. No.:

13/941821

Inventors:

Brian William Higgins - Dayton MD, US

International Classification:

H04L 29/08

US Classification:

709217

Abstract:

A system and method for effectively communicating information using at least one mode of communication is described, in which information recipients proximate to a communications device within a pre-determined space and during a pre-determined time period are identified, from whom physiological state information is obtained that, when coupled with other characteristics information, is used to select from a plurality of information elements at least one information element to better target the information elements. The information element is then provided to the communications device so that it may be provided to the information recipients in the pre-determined space in a manner that is sensed by the information recipients.